This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
Zacks Market Edge Highlights: WBA, TROW, ITW, NUS, WSM
by Zacks Equity Research
WBA, TROW, ITW, NUS and WSM have been highlighted in this Market Edge article.
Looking for High Yields? Check the Dividend Aristocrats
by Tracey Ryniec
Getting a 5% yield isn't easy but here's some tips for finding the stocks.
Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $40.54, moving -1.75% from the previous trading session.
Company News for Nov 14, 2022
by Zacks Equity Research
Companies in The News Are: WBA, AMZN, COIN, AQN
Should Investors Buy CVS Stock Before Q3 Earnings?
by Shaun Pruitt
Trading 15% from its highs, CVS (CVS) is set to report Q3 earnings on Wednesday, November 2. Investors hope the company can capitalize on its ambition to sustain itself as an industry leader as the Retail-Pharmacies Drug Stores Industry is currently in the top 18% of over 250 Zacks Industries.
Online Strength to Drive Rite Aid (RAD) Amid Supply-Chain Woes
by Zacks Equity Research
Rite Aid (RAD) remains well-placed on online strength, increased non-COVID prescriptions and cost initiatives despite muted COVID-19 testing and vaccine demand, and supply-chain issues.
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Rite Aid and Amazon's
by Zacks Equity Research
CVS Health, Walgreens Boots Alliance, Rite Aid and Amazon's are part of Zacks Industry Outlook article.
3 Retail Pharmacy and Drugstore Stocks to Watch Amid Industry Challenges
by Urmimala Biswas
The Zacks Retail Pharmacy and Drugstore industry players like CVS, WBA and RAD are likely to gain from the growing demand for digital healthcare support. However, reimbursement challenges are hurting overall industry health.
Walgreens Boots (WBA) Q4 Earnings Top, Operating Loss Concerns
by Zacks Equity Research
The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution.
Walgreens Boots Alliance (WBA) Beats Q4 Earnings Estimates
by Zacks Equity Research
Walgreens (WBA) delivered earnings and revenue surprises of 2.56% and 0.13%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
Markets Flattish Ahead of CPI, Jobless Claims, Q3 Earnings
by Mark Vickery
Thursday's CPI report is arguably the single-most important data point ahead of the next Fed meeting.
Company News for Oct 12, 2022
by Zacks Equity Research
Companies In The News Are: AAL, CS, WBA, UBER.
Walgreens Earnings Preview: Can WBA Stock Rebound?
by Shaun Pruitt
WBA's upcoming earnings release on Thursday, October 13 will be closely monitored as many businesses struggle amid rising inflation and tougher operating environments. Investors will want to see some upbeat guidance more than anything else.
Wall Street Waits for Q3 2022 Earnings to Kick Off
by Zacks Equity Research
Wall Street Waits for Q3 2022 Earnings to Kick Off.
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Walgreens (WBA) is expected to have registered growth in Q4 in its U.S. retail pharmacy business, banking on demand for vaccinations and tests amid the ongoing series of contagious virus spread.
Big Week for Data, Earnings Starts Quiet
by Mark Vickery
The big news for the week will be along two paths: CPI data for September and the start of Q3 earnings season.
Analysts Estimate Walgreens Boots Alliance (WBA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Walgreens (WBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $33.16 in the latest trading session, marking a -0.69% move from the prior day.
Rite Aid (RAD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rite Aid (RAD) delivered earnings and revenue surprises of -36.96% and 0.66%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
Walgreens Boots Alliance (WBA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $32.43, moving -0.8% from the previous trading session.
Walgreens Boots' (WBA) Product Expansion Aids Amid Rivalry
by Zacks Equity Research
Sales contributions from Walgreens Boots' (WBA) newly-formed Walgreens Health segment instill investors' optimism.
Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXG
Walgreens Boots Alliance (WBA) Stock Moves -1.65%: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $33.43, moving -1.65% from the previous trading session.